

1  
2  
3  
4 **Sustained release of calcium hydroxide from poly (DL lactide-co-glycolide) acid**  
5  
6 **microspheres for apexification.**  
7  
8

9  
10 Bernardino Isaac Cerda-Cristerna <sup>1</sup>, Alejandro Breceda-Leija <sup>1</sup>, Verónica Méndez-  
11 González<sup>1</sup>, Daniel Chavarría-Bolaños <sup>2</sup>, Héctor Flores-Reyes <sup>1</sup>, Arturo Garrocho-Rangel <sup>3</sup>,  
12 Takashi Komabayashi <sup>4</sup>, Aniket Wadajkar <sup>5</sup>, Amaury J. Pozos-Guillén<sup>1</sup>  
13  
14

15  
16 1. Postgraduate Endodontics Program, Faculty of Dentistry, Universidad Autónoma de San  
17 Luis Potosí, San Luis Potosí, San Luis Potosí, Mexico.  
18

19  
20 2. Diagnostic and Surgical Sciences Department, Faculty of Dentistry, Universidad de Costa  
21 Rica, San José, Costa Rica.  
22

23  
24 3. Postgraduate Pediatrics Dentistry Program, Universidad Autónoma de San Luis Potosí,  
25 San Luis Potosí, San Luis Potosí, Mexico.  
26

27  
28 4. Postgraduate Endodontics Program, West Virginia University, Morgantown, West  
29 Virginia, United States.  
30

31  
32 5. Department of Bioengineering, University of Texas at Arlington, , Arlington, Texas,  
33 United States.  
34

35  
36 **Correspondence:** Dr. Bernardino Isaac Cerda Cristerna, Faculty of Dentistry, Postgraduate  
37 Endodontics Program, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava  
38 #2, Zona Universitaria, CP 78290, San Luis Potosí, SLP, Mexico. E-mail:  
39 bernardino.cerda@uaslp.mx. Phone: +52 444 826 23 00, EXT 5134.  
40  
41  
42  
43  
44  
45  
46

47 **Abstract**  
48  
49

50 Calcium hydroxide (Ca(OH)<sub>2</sub>) loaded poly(DL-lactide-co-glycolide) acid (PLGA)  
51 microspheres (MS) might be employed for apexification requiring a sustained release of  
52 Ca<sup>++</sup>. The aim of this study was to formulate and characterize Ca(OH)<sub>2</sub>-PLGA-MS. The  
53 Ca(OH)<sub>2</sub>-loaded MS were prepared by either oil-in-water (O/W) or water-in-oil/in-water  
54 (W/O/W) emulsion solvent evaporation technique. MS produced by the O/W technique  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 exhibited a larger diameter ( $18.63 \pm 7.23 \mu\text{m}$ ) than the MS produced by the W/O/W  
5  
6 technique ( $15.25 \pm 7.37 \mu\text{m}$ ) (Mann Whitney U test  $P < 0.001$ ). The  $\text{Ca}(\text{OH})_2$  encapsulation  
7  
8 efficiency and  $\text{Ca}^{++}$  release were calculated from data obtained by absorption techniques.  
9  
10  $\text{Ca}^{++}$  release profile was evaluated for 30 days. The percentage of encapsulation efficiency  
11  
12 of the O/W-produced MS was higher (24%) than the corresponding percentage of the  
13  
14 W/O/W-produced MS (11%). O/W- and W/O/W-produced MS released slower and lower  
15  
16  $\text{Ca}^{++}$  than a control  $\text{Ca}(\text{OH})_2$  paste with polyethylene glycol 400 (ANOVA 1 way, Tukey  
17  
18 HSD  $P < 0.01$ ). O/W-produced MS released higher  $\text{Ca}^{++}$  than W/O/W-produced MS  
19  
20 (statistically significant differences with t-Student test). We concluded that  $\text{Ca}(\text{OH})_2$ -  
21  
22 PLGA-MS were successfully formulated; the technique of formulation influenced on the  
23  
24 size, encapsulation efficiency and release profile. The MS were better sustained release  
25  
26 system than the  $\text{Ca}(\text{OH})_2$  paste.  
27  
28  
29  
30  
31  
32  
33

34 **Key words:** apexification, calcium hydroxide, microspheres, poly(DL-lactide-co-glycolide)  
35  
36 acid, sustained drug delivery system.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

Apexification is the induction of apical closure to produce favorable conditions for conventional root canal filling [1]. Calcium hydroxide ( $\text{Ca}(\text{OH})_2$ ) is widely used for apexification treatment because of its ability to induce mineral tissue formation and apical closure [1, 2]. The  $\text{Ca}(\text{OH})_2$  releases calcium ions ( $\text{Ca}^{++}$ ) and hydroxyl ions; the  $\text{Ca}^{++}$  and the local increase of pH ( $\sim 12.5$ ) in the tissues induce cellular activity promoting the mineral tissue formation [3-5]. Because the apexification is a long-term treatment, it requires sustained release of  $\text{Ca}^{++}$  from the  $\text{Ca}(\text{OH})_2$  and usually to achieve that condition, the  $\text{Ca}(\text{OH})_2$  is replaced on multiple appointments [2]. Thus a biodegradable sustained drug delivery system (SDDS) loaded with  $\text{Ca}(\text{OH})_2$  might be useful for apexification because the SDDS would release  $\text{Ca}^{++}$  during long time with a single application.

Among SDDS technologies, microspheres (MS) formulated with polymers have showed efficacy to promote sustained release of  $\text{Ca}^{++}$  [6-8]. Hunter et al. manufactured calcium citrate loaded poly(ethylenglycol)-MS within a range size of 180-2000  $\mu\text{m}$  releasing  $\text{Ca}^{++}$  for 3-4 days but for pulp capping [6, 7]. For apexification, Strom et al. produced alginate-based MS loaded with  $\text{Ca}(\text{OH})_2$  to promote long term release of  $\text{Ca}^{++}$ ; the MS showed a longer sustained  $\text{Ca}^{++}$  release profile than that of a  $\text{Ca}(\text{OH})_2$  paste prepared with distilled water [8]. Despite the few approaches to research polymer-based MS for  $\text{Ca}^{++}$  sustained release, the studies have ignored the use of a biomaterial with advantageous physicochemical properties for such purpose: the poly (DL-lactide-co-glycolide) acid (PLGA). The PLGA is a biodegradable and biocompatible polymer approved for human use by the FDA; its degradation in tissues initiates by hydrolysis of the ester linkages of the polymer chain giving the innocuous lactic acid and glycolic acid [9]. Acting as matrix of a

1  
2  
3  
4 MS, the PLGA might entrap a biomolecule that will be released while the polymer  
5 degradation occurs, this action results in a sustained release that depends on PLGA  
6 properties but also on the characteristics of the MS [10, 11]. Accordingly we suggest to  
7 explore the formulation of a sustained release system of Ca(OH)<sub>2</sub> loaded PLGA-MS for  
8 apexification.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 The aim of this study was to formulate and characterize Ca(OH)<sub>2</sub> loaded PLGA-MS  
20 (CMS). To achieve this purpose, we performed two techniques – oil-in-water (O/W) single  
21 emulsion or water-in-oil-in-water (W/O/W) double emulsion– based on the solvent  
22 evaporation method to compare physical properties of the CMS and Ca<sup>++</sup> release profile.  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Materials and Methods**

32  
33 Poly (DL-lactide-co-glycolide) (ratio lactide:glycolide 75/25; mol wt 66,000-107,000 kDa),  
34 dichloromethane anhydride (DCM) ≥99.8% solvent, Polyethylene glycol (PEG; Mn 400)  
35 and polyvinyl alcohol (PVA) (87.90 % hydrolyzed) were purchased from Sigma-Aldrich  
36 (St Louis, MO,USA). Calcium hydroxide was purchased from Viarden (Mexico City, DF,  
37 MX). All reagents were of analytical grade.  
38  
39  
40  
41  
42  
43  
44

#### 45 *Preparation of the microspheres*

##### 46 *Oil-in-water single-emulsion solvent evaporation technique (W/O)*

47  
48 The O/W technique was based and adapted from methodologies previously reported [12,  
49 13]. Briefly, 20 mg Ca(OH)<sub>2</sub> and 200 mg PLGA were added into a 10 mL glass tube  
50 containing 2 mL DCM, this oil phase (drug/matrix dispersion) was vortexed with a Maxi  
51 Mix II vortex (Thermo Scientific, Pittsburgh, PA, USA) at maximum speed for 3 min.  
52  
53 Immediately after that, the oil phase was added drop-wise into a 250 mL glass baker  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 containing a 100 mL 1% PVA (continues phase) under stirring at 800 rpm (25°C) (Corning  
5 PC 4200 stirring hot plate, Corning, NY, USA). After that 100 mL of distilled water was  
6 added. Then, the stirring continued for 3 h to promote evaporation of DCM. After finishing  
7 the stirring, the formed MS were recovered by filtration through a filter paper (2 µm Filter  
8 Paper Ahlstrom, Monterrey, NL MEX) and were profusely washed with distilled water.  
9 Finally the MS were freeze-dried (Freeze Dry System Freezone 6, Labconco, Kansas City,  
10 MI, USA) for 4 h and stored at 4°C until its characterization and evaluation of Ca<sup>++</sup>  
11 release. The Ca(OH)<sub>2</sub> loaded MS were identified as oCMS. Blank control MS were  
12 produced following the same method without Ca(OH)<sub>2</sub>.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

#### 28 *Water-in-oil-in-water method double-emulsion solvent evaporation technique (W/O/W)*

29 The WOW procedure was based and adapted from techniques already reported [12, 13].  
30 Briefly, a 20 mg/mL Ca(OH)<sub>2</sub> dispersion was prepared with double distilled water. This  
31 dispersion and 200 mg PLGA were added into a 10 mL glass tube containing 2 mL DCM,  
32 this oil phase (drug/matrix dispersion) was vortexed with a Maxi Mix II vortex (Thermo  
33 Scientific, Pittsburgh, PA, USA) at maximum speed for 3 min. After that, the procedure  
34 was performed as described in the paragraph above (see O/W process). The Ca(OH)<sub>2</sub>  
35 loaded MS were identified as wCMS. Blank control MS were produced with the same  
36 method without Ca(OH)<sub>2</sub>.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

#### 50 *Characterization of the MS*

##### 51 *Morphology of the MS*

52 Morphology was observed using 1-2 mg MS. They were put on an adhesive tape, and then  
53 it was coated with gold (20 mA for 4 minutes). The gold-coated MS were observed by a  
54 scanning electronic microscope (Philips XL-30, Philips, Hillsboro, OR, USA).  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 *Particle size analysis of the microspheres*

8  
9 Microspheres were imaged at 100x using a light microscope with a digital camera  
10 (Olympus, Center Valley, PA, USA). Images were analyzed with ImageJ Software  
11 (Version 1.45, National Institutes of Health, Bethesda, MD, USA); one hundred of MS  
12 were measured and its average diameter was calculated. A Mann Whitney U test was  
13 applied to identify a possible statistical significant difference between CMS and blank MS  
14 as well as between oCMS and wCMS. Statistical significance was set at  $p < 0.05$ .  
15  
16  
17  
18  
19  
20  
21  
22

23 *Encapsulation efficiency (Ee)*

24  
25 To calculate the Ee, Ca(OH)<sub>2</sub>-loaded MS were dissolved in 1 M NaOH. In this dissolution,  
26 a calcium colorimetric marker (Calcio Arsenazo III, Bio Simex, Guadalajara, JAL, MEX)  
27 was added for 5 minutes to react with Ca<sup>++</sup>. The reagent caused a blue color in the samples  
28 thus absorbance of the samples was measured by a UV-VIS system at 650 nm (Cary 50  
29 UV-Visible Spectroscopy System, Agilent Technologies, Mexico City, MEX). A  
30 calibration curve was previously performed to obtain the calcium concentration in relation  
31 to absorbance values. Ee was calculated as the ratio of the experimental loading to the  
32 theoretical loading, of the drug in the microspheres.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 *Ca<sup>++</sup> release*

46  
47 Twenty mg of either oCMS or wCMS was suspended into 1 mL deionized water in an  
48 Eppendorf tube (1.5 mL) and incubated at 37°C for 30 days and shook at 150 rpm (Incu-  
49 Shaker Mini, Benchmark Scientific; Edison, NJ, USA). The deionized water of the  
50 Eppendorf tubes was collected at different times; then 1 mL fresh deionized water was  
51 added in the Eppendorf tube containing the CMS. For Ca<sup>++</sup> measuring, the Ca<sup>++</sup> in the  
52 collected supernatant was marked with a calcium colorimetric marker (Calcio Arsenazo III,  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Bio Simex, Guadalajara, JAL, MEX) and measured by a UV-VIS system at 650 nm (Cary  
5  
6 50 UV-Visible Spectroscopy System, Agilent Technologies, Mexico City, MEX). Ca<sup>++</sup>  
7  
8 concentration was calculated from the absorbance in the basis of a calibration curve  
9  
10 performed previously. Ca<sup>++</sup> release of experimental groups was compared with a Ca<sup>++</sup>  
11  
12 release of a control paste prepared with Ca(OH)<sub>2</sub> and PEG 400 (1.5 mg/10 μL). We  
13  
14 incubated the Ca(OH)<sub>2</sub> paste in a 1.5 cm length dialysis tubing cellulose membrane (Avg.  
15  
16 flat width 10 mm; typical molecular weight cut-off = 14,000; Sigma-Aldrich, St. Louis,  
17  
18 MO, USA) with a seal in each extremity. The membrane was used only for the control  
19  
20 paste to avoid its immediate dispersion in the deionized water. The membrane with the  
21  
22 paste was suspended into 1 mL deionized water in an Eppendorf tube (1.5 mL) and  
23  
24 incubated at 37°C for 30 days and shook at 150 rpm. The measurement of Ca<sup>++</sup> was  
25  
26 identically as described for the CMS. All experiments were done in triplicate. ANOVA one  
27  
28 way test and Tukey HSD test were applied to identify possible statistical significant  
29  
30 differences between Ca<sup>++</sup> release profiles of control and CMS. Statistical significance was  
31  
32 set at  $P < 0.01$ . T-student was applied to identify possible statistical significant differences  
33  
34 between Ca<sup>++</sup> release profiles of oCMS and wCMS.  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **Results**

45  
46 CMS with a similar spherical morphology were obtained with two emulsion solvent  
47  
48 evaporation techniques. The CMS exhibited different topographical characteristics  
49  
50 depending on the preparation method (Figure 1). The oCMS showed an average diameter of  
51  
52  $18.63 \pm 7.23 \mu\text{m}$ , while the wCMS showed a diameter of  $15.25 \pm 7.36 \mu\text{m}$ . No statistical  
53  
54 difference in diameter was found between CMS and blank MS. Significantly statistical  
55  
56 difference was noticed ( $P < 0.001$ ) between average diameter of oCMS and wCMS.  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Calculation of Ee was 24% for oCMS, while it was 11% for the wCMS. Compared with the  
5  
6 control paste, the CMS showed a lower and longer Ca<sup>++</sup> releasing activity; the figure 2  
7  
8 shows the Ca<sup>++</sup> releasing activity of the CMS and the control.  
9

## 10 11 **Discussion**

12  
13 We explored the formulation of CMS by the solvent extraction/evaporation method. In this  
14  
15 method a drug/matrix oily dispersion is partitioned into microdroplets when it is added in  
16  
17 an aqueous phase under shear forces. Then, extraction/evaporation of the solvent induces  
18  
19 PLGA crystallization transforming the microdroplets into solid MS. We employed two  
20  
21 variants of the method, O/W and W/O/W techniques. They differed in the physical  
22  
23 presentation of the Ca(OH)<sub>2</sub> for the dispersed phase, which was employed as a powder for  
24  
25 the O/W and diluted in distilled water for the W/O/W techniques. The wCMS showed a  
26  
27 rough like-porous surface while the oCMS showed a smooth surface; the average diameter  
28  
29 of the MS was another property varying between the wCMS and the oCMS, these latter  
30  
31 were the largest ones. The size of the MS depends on factors controlled by the formulation  
32  
33 technique, for instance speed of stirring, temperature of the aqueous phase, or mass content  
34  
35 in the dispersed phase [12]. In our study, the phase for the O/W presented larger solid  
36  
37 content than the dispersed phase for the W/O/W. In that condition, a dispersed phase is  
38  
39 more resistant against the shear forces causing its partitioning into droplets, and  
40  
41 consequently larger MS are produced [14]. The oCMS entrapped over twice Ca(OH)<sub>2</sub> than  
42  
43 the wCMS. Higher Ee in oCMS is explained because higher DMC volume in the O/W  
44  
45 dispersed phase reduces the flux of the used biomolecule (Ca(OH)<sub>2</sub> in our case) to aqueous  
46  
47 phase during solvent extraction/evaporation, and also accelerate PLGA crystallization with  
48  
49 a consequent increase in the entrapment of the drug [15]. It should be considered that  
50  
51 Ca(OH)<sub>2</sub> is an hydrophilic molecule that easily might go to the aqueous phase from the  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 dispersed phase causing a low Ee. We determined whether CMS released lower Ca<sup>++</sup>  
5  
6 compared to Ca<sup>++</sup> released from a Ca(OH)<sub>2</sub> paste formulated with PEG 400, a fluid  
7  
8 polymer used to promote slow and sustained release of Ca<sup>++</sup> [2, 16, 17]. The paste showed  
9  
10 a burst release of 42.6% Ca<sup>++</sup> after 1 day of evaluation; then the paste showed a release of  
11  
12 86.3% Ca<sup>++</sup> after 3 days and finally it showed a release of 100% Ca<sup>++</sup> after 6 days. The  
13  
14 PEG is a highly hydrophilic polymer, thus it was rapidly dissolved in the PBS under our  
15  
16 experimental conditions resulting in a fast release of the Ca<sup>++</sup>. The CMS behaved as a  
17  
18 more efficient slow and sustained release system compared to the Ca(OH)<sub>2</sub> paste indeed. In  
19  
20 the CMS, the Ca(OH)<sub>2</sub> was entrapped into the PLGA matrix during the MS formulation and  
21  
22 it was released in a slow and sustained manner because of the gradual degradation of the  
23  
24 polymer matrix during the evaluation time. The CMS kept a Ca<sup>++</sup> release for 30 days.  
25  
26 During first 9 days of evaluation a similar Ca<sup>++</sup> release profile was noticed for both oCMS  
27  
28 and wCMS, but since day 12th, the Ca<sup>++</sup> release profiles behaved different in both CMS.  
29  
30 We correlated the difference between release profiles to the surface properties of the MS. A  
31  
32 rough like-porous surface favors a rapid drug release because fluids penetrate easier into  
33  
34 the MS matrix and facilitates degradation of PLGA, releasing the entrapped drug; in the  
35  
36 contrary, a smooth surface delays drug release [18,19]. It can also be correlated the fact that  
37  
38 wCMS loaded less Ca(OH)<sub>2</sub>, as demonstrated by the percentage of Ee, and this was  
39  
40 reflected on the release profile.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Our study is the first one researching Ca(OH)<sub>2</sub> loaded PLGA-based MS for apexification.  
54  
55 Others have explored MS for the same purpose. Strom et al. produced Ca(OH)<sub>2</sub> loaded  
56  
57 alginate MS (CAMS) crosslinked by the Ca<sup>++</sup> in the polymer matrix [8]. They compared  
58  
59 the CAMS to a Ca(OH)<sub>2</sub> paste (with distilled water; CP) and Ultracal XS calcium  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 hydroxide paste (UC) [8]. After 4 days, the CAMS released similar Ca<sup>++</sup> amount to that  
5  
6 released from UC but lower to that released from the CP [8]. After 10 days the CAMS  
7  
8 released significantly lower Ca<sup>++</sup> than both CP and UC; at 1 month the CAMS released  
9  
10 ~18% of its Ca<sup>++</sup> content [8]. Although the CAMS and our CMS are different in their  
11  
12 characteristics, both systems showed a better sustained release profile when compared to a  
13  
14 Ca(OH)<sub>2</sub> paste.  
15  
16  
17  
18  
19  
20

21 We choose PLGA to produce the MS because of its biocompatibility and biodegradability.  
22  
23 The CMS were a micro-granular material ad hoc to be introduced into a root canal by a  
24  
25 double-ended spatula for cement. When needed, the CMS might be easily removed from  
26  
27 the root canal by flushing with distilled water followed by aspiration. If the CMS were  
28  
29 located at extra-radicular area –as might occur for apexification– they will be biodegraded  
30  
31 by action of the tissue fluid [12]. Thus the CMS might be placed into the root canal at  
32  
33 apical level intending a single application of a SDDS. Using CMS might overcome  
34  
35 disadvantages of Ca(OH)<sub>2</sub> paste for apexification such as replacement of paste requiring  
36  
37 multiple visits but also risk of root fracture by Ca(OH)<sub>2</sub> dressing [20-22].  
38  
39  
40  
41  
42  
43

44 We are aware of the limitations of this study. Evaluation time for 30 days was suitable to  
45  
46 explore the release profile but it was short for a clinical reality; also the evaluation was  
47  
48 short to know the time in which both oCMS and wCMS releases the total content of Ca<sup>++</sup>.  
49  
50 We obtained an Ee 3 times lower than the total amount of Ca(OH)<sub>2</sub> employed in the  
51  
52 formulation of the CMS, the technique should improve to get a higher Ee.  
53  
54  
55  
56

57 We concluded that CMS were successfully formulated, the techniques employed to produce  
58  
59 them influenced on their characteristics. The CMS showed a size suitable for its application  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 into a root canal. The CMS showed a Ca<sup>++</sup> sustained releasing activity for 30 days and it  
5  
6 was better than that of the Ca(OH)<sub>2</sub> paste.  
7  
8  
9

### 10 **Acknowledgements**

11  
12 This work was partially supported by PIFI 2011-12, UASLP-C12-FAI-03-45.45 grants. We  
13 would like to thank American Journal Experts, for their assistance in editing this  
14 manuscript.  
15  
16  
17  
18  
19  
20

### 21 **References**

- 22 1. Rafter M. Apexification: a review. Dent Traumatol. 2005;2:1-8.
- 23 2. Mohammadi Z, dummer PM. Properties and applications of calcium hydroxide in  
24 endodontics and dental traumatology. Int Endod J. 2011;44:697-730.
- 25 3. Tronstad L, Andreasen JO, Hasselgren G, Kristerson L, Riis I. ph changes in dental  
26 tissues after root canal filling with calcium hydroxide. J Endod. 1981;7:17-21.
- 27 4. Rashid F, Shiba H, Mizuno N, Mouri Y, Fujita T, Shinohora H, Ogawa T, Kawaguchi H,  
28 Kurihara H. the effect of extracellular calcium ion on gene expression of bone-related  
29 proteins in human pulp cells. J Endod. 2003;29:104-7.
- 30 5. Narita H, Itoh S, Imazato S, Yoshitake F, Ebisu S. An explanation of the mineralization  
31 mechanism in osteoblasts induced by calcium hydroxide. Acta Biomater. 2010;6:586-90.
- 32 6. Hunter AR, Kirk EE, Robinson DH, Kardos TB. A slow release calcium delivery system  
33 for the study of reparative dentine formation. Endod Dent Traumatol. 1998;14:112-8.
- 34 7. Hunter AR, Kirk EE, Robinson DH, Kardos TB. In vitro characterization of  
35 poly(ethylene) glycol calcium citrate microspheres as a delivery system for the study of  
36 reparative dentinogenesis. Endod Dent Traumatol. 1998;14:159-62.
- 37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 8. Strom TA, Arora A, Osborn B, Karim N, Komabayashi T, Liu X. Endodontic release  
5 system for apexification with calcium hydroxide microspheres. *J Dent Res.* 2012; 91:1055-  
6  
7  
8  
9 9.
- 10  
11 9. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro  
12 technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000
- 11 9. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro  
12 technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000
- 10 10. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA  
11 microspheres. *Adv Drug Deliver Rev.* 1997;28:5-24.
- 12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500

- 1  
2  
3  
4 15. Porjazoska A, Goracinova K, Mladenovska K, Glavas M, Simonovska M, Janjević EI,  
5  
6 Cvetkovska M. Poly(lactide-co-glycolide) microparticles as systems for controlled release  
7  
8 of proteins -- preparation and characterization. *Acta Pharm.* 2004;54 :215-29.  
9  
10  
11 16. Tanomaru Filho M, Leonardo MR, da Silva LA. Effect of irrigating solution and  
12  
13 calcium hydroxide root canal dressing on the repair of apical and periapical tissues of teeth  
14  
15 with periapical lesion. *J Endod.* 2002;28:295-9.  
16  
17  
18 17. Ballal NV, Shavi GV, Kumar R, Kundabala M, Bhat KS. In vitro sustained release of  
19  
20 calcium ions and pH maintenance from different vehicles containing calcium hydroxide. *J*  
21  
22 *Endod.* 2010;36:862-6.  
23  
24  
25 18. Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of WOW process  
26  
27 parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres.  
28  
29 *Int J Pharm.* 2007; 334:137-48.  
30  
31  
32 19. Yang Y-Y, Chung T-S, Bai X-L, Chan W-K. Effect of preparation conditions on  
33  
34 morphology and release profiles of biodegradable polymeric microspheres containing  
35  
36 protein fabricated by double-emulsion method. *Chem Eng Sci.* 2000;55:2223-36.  
37  
38  
39 20. Huang GT. Apexification: the beginning of its end. *Int Endod J.* 2009;42:855-66.  
40  
41  
42  
43 21. Cvek M. Prognosis of luxated non-vital maxillary incisors treated with calcium  
44  
45 hydroxide and filled with gutta-percha. A retrospective clinical study. *Endod Dent*  
46  
47 *Traumatol.* 1992;8:45-55.  
48  
49  
50 22. Andreasen JO, Farik B, Munksgaard EC. Long-term calcium hydroxide as a root canal  
51  
52 dressing may increase risk of root fracture. *Dent Traumatol.* 2002;18:134-7.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Figure captions**  
5  
6

7 **Fig 1** SEM images (1000x) showing the morphological properties of the two types of  
8 Ca(OH)<sub>2</sub> loaded microspheres. Oil-in-water produced microspheres (oCMS) shows a  
9 spherical morphology with a smooth surface (A). Water-in-oil/in-water produced  
10 microspheres (wCMS) shows a spherical morphology with a porous and like-rough surface  
11 (B). Blank microspheres (C)  
12  
13  
14  
15  
16  
17  
18  
19

20 **Fig 2** Ca<sup>++</sup> accumulative release profile (A) and release percentage (B). The control  
21 (Ca(OH)<sub>2</sub> with polyethylene glycol 400) released 401.1 ± 128.5 µg/mL, 700.3 ± 38.9  
22 µg/mL and 811.2 ± 26.3 µg/mL after 1, 3 and 6 days of evaluation, respectively. At 6 days,  
23 the control released 100% of Ca<sup>++</sup> (B). The control showed a Ca<sup>++</sup> release profile shorter  
24 than that of the oCMS (oil-in-water produced microspheres) and wCMS (water-in-oil/in-  
25 water produced microspheres); statistically significant differences between the control and  
26 oCMS and wCMS were found at (\*) (A). The oCMS and wCMS exhibited a similar release  
27 profile after 9 days of evaluation (A). But at (#) significantly statistical differences were  
28 found between the Ca<sup>++</sup> released amounts from oCMS (430.5 ± 63.4 µg/mL) and wCMS  
29 (292.8 ± 50.7 µg/mL), the differences were observed up to the end of the experiment. The  
30 total released Ca<sup>++</sup> was 590.1 ± 89.0 µg/mL for the oCMS and 297.9 ± 50.6 µg/mL for the  
31 wCMS; that represented 76.6% and 90.9% of Ca<sup>++</sup> for the oCMS and wCMS, respectively  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65





